Equities research analysts expect DURECT Corporation (NASDAQ:DRRX) to announce $5.17 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for DURECT Corporation’s earnings. The lowest sales estimate is $3.40 million and the highest is $8.50 million. DURECT Corporation reported sales of $3.16 million during the same quarter last year, which suggests a positive year-over-year growth rate of 63.6%. The firm is scheduled to issue its next quarterly earnings results after the market closes on Tuesday, August 8th.

On average, analysts expect that DURECT Corporation will report full-year sales of $5.17 million for the current financial year, with estimates ranging from $15.62 million to $36.70 million. For the next year, analysts expect that the firm will post sales of $31.94 million per share, with estimates ranging from $14.31 million to $42.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for DURECT Corporation.

DURECT Corporation (NASDAQ:DRRX) last posted its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The firm had revenue of $4.57 million during the quarter, compared to analyst estimates of $3.60 million. DURECT Corporation had a negative net margin of 232.05% and a negative return on equity of 318.49%.

Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus raised shares of DURECT Corporation from a “hold” rating to a “buy” rating and upped their target price for the stock from $1.25 to $3.00 in a report on Wednesday, July 12th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of DURECT Corporation in a report on Sunday, June 25th.

Several large investors have recently bought and sold shares of the company. Ingalls & Snyder LLC raised its stake in DURECT Corporation by 213.1% in the second quarter. Ingalls & Snyder LLC now owns 6,419,482 shares of the specialty pharmaceutical company’s stock valued at $10,014,000 after buying an additional 4,369,400 shares during the last quarter. Gagnon Securities LLC raised its stake in DURECT Corporation by 35.9% in the second quarter. Gagnon Securities LLC now owns 1,283,954 shares of the specialty pharmaceutical company’s stock valued at $2,003,000 after buying an additional 338,881 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in DURECT Corporation during the first quarter valued at $118,000. Ironwood Investment Management LLC raised its stake in DURECT Corporation by 0.6% in the first quarter. Ironwood Investment Management LLC now owns 472,029 shares of the specialty pharmaceutical company’s stock valued at $496,000 after buying an additional 2,785 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its stake in DURECT Corporation by 28.6% in the first quarter. Stonepine Capital Management LLC now owns 2,801,376 shares of the specialty pharmaceutical company’s stock valued at $2,941,000 after buying an additional 623,585 shares during the last quarter. 49.71% of the stock is currently owned by institutional investors and hedge funds.

DURECT Corporation (DRRX) traded down 0.59% on Friday, reaching $1.69. 192,719 shares of the company’s stock were exchanged. The firm’s market capitalization is $239.92 million. The firm has a 50-day moving average of $1.62 and a 200-day moving average of $1.19. DURECT Corporation has a 12 month low of $0.74 and a 12 month high of $1.95.

TRADEMARK VIOLATION WARNING: “DURECT Corporation (NASDAQ:DRRX) Expected to Announce Quarterly Sales of $5.17 Million” was originally posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/06/durect-corporation-nasdaqdrrx-expected-to-announce-quarterly-sales-of-5-17-million.html.

DURECT Corporation Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Get a free copy of the Zacks research report on DURECT Corporation (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.